Longevity Science — 2026-09-11
This week, a new study published in *Nature Biotechnology* validated the use of proteomic aging clocks to assess geroprotective effects in a Phase 2a clinical trial. In the industry sector, Moonwalk Therapeutics secured $70 million in Series B funding for adipose-targeted RNAi, while GlycanAge expanded its aging science operations into Japan.
Longevity Science — 2026-09-11
Top Research Findings
Integration of Proteomic Aging Clocks in Clinical Trials Researchers developed a framework using serum samples screened via the Olink Explore 3072 platform to obtain longitudinal proteomic profiles. The study, published in Nature Biotechnology, demonstrates that multi-clock monitoring can simultaneously assess aging rates and compare trajectories against senescence-associated genesets in a Phase 2a trial setting. This validates the utility of proteomic clocks as robust biomarkers for evaluating the efficacy of anti-aging interventions in humans.
Clinical Trials & Intervention Updates
BioAge Labs Initiates Phase 2 Trial for Diabetic Vision Loss BioAge Labs has begun a Phase 2 clinical trial for a daily pill targeting diabetic vision loss. This intervention aligns with the company’s broader strategy of leveraging AI to identify age-related disease targets. The trial represents a continued effort to translate longevity insights into treatments for specific degenerative conditions associated with metabolic dysfunction.
Rentosertib Advances with Aging Clocks Rentosertib is currently putting aging clocks to the clinical test, marking a shift toward interventions that are explicitly monitored using these biological age markers. While specific phase data was not detailed in the headline, the focus on "clinical test" alongside aging clocks suggests an emphasis on validating the drug's ability to reverse or slow measurable aging parameters.
Industry & Biotech Watch
Moonwalk Raises $70M for Adipose-Targeted RNAi Moonwalk Therapeutics announced a $70 million Series B funding round. The capital will advance their pipeline of adipose-targeted RNAi therapies. By targeting adipose tissue specifically, the company aims to address metabolic drivers of aging and chronic disease through precision gene silencing.
GlycanAge Partners with Japan on Aging Science GlycanAge, known for its glycan-based biological age testing, has teamed up with partners in Japan to expand its aging science initiatives. This international collaboration aims to broaden the application and validation of glycan analysis as a tool for assessing biological age and healthspan.
Deep Dive: Intervention Evidence Check
Rapamycin: Dose-Dependent Immune Effects Current evidence highlights a critical distinction in rapamycin usage based on dosage. At continuous high doses used in transplant medicine, rapamycin suppresses immune function. However, at low intermittent doses used in longevity trials (such as those referenced in recent 2026 mechanistic data), evidence suggests an improvement in immune function, including vaccine response, in older adults. Recent studies indicate this may be due to reduced cellular senescence rather than immune suppression, providing a cellular explanation for the "geroprotective" effects observed in aging humans.
What to Watch Next
- Coya’s Combination Drug: Monitoring further results from Coya’s combination drug which showed promise against neuroinflammation in mouse studies, potentially moving toward human trials.
- Alzheon’s Phase 3 Follow-up: Following Alzheon’s reported Phase 3 win for an Alzheimer’s treatment targeted at high-risk genetic carriers, long-term safety and efficacy data will be scrutinized.
Reader Action Items
- Review Biological Age Markers: Consider exploring proteomic or glycan-based biological age tests (like those offered by GlycanAge) as discussed in recent industry updates, to establish a baseline for healthspan tracking.
- Discuss Rapamycin Dosage: If you are currently taking or considering rapamycin, discuss the distinction between continuous vs. intermittent dosing with your healthcare provider, citing recent evidence on immune modulation in older adults.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
